Caligor Enhances Operational And Commercial Leadership To Meet Growing Global Demand For Its Clinical Trial Supply Services
SECAUCUS, N.J.--(BUSINESS WIRE)--Following a record year for its clinical trial supply and global access services in 2016, Caligor Opco LLC today further enhanced its operational and commercial leadership teams, appointing David Edwards as its new Chief Executive Officer. Tammy Bishop will assume the new role of Chief Commercial Officer and continue to be a member of the Board of Directors.
Mr. Edwards will be based at Caligor’s European headquarters in Dartford, UK, which includes the Company’s new state-of-the-art storage and distribution facility. Mr. Edwards has broad management experience with leading healthcare companies and a successful track record of growing businesses in the U.S., Europe and Asia. Most recently he was the East Asia Vice President for Alcon, a Novartis company and a global leader in eye care. Mr. Edwards also served as President of the Asia-Pacific region at Bausch & Lomb and spent more than a decade in executive management positions at Johnson & Johnson. He was President of Johnson & Johnson’s diabetes business unit in Europe, the Middle East and Africa, led the Johnson & Johnson Vision Care business in the Asia-Pacific region and headed Johnson & Johnson’s Consumer Nutritionals business in Europe.
“David is a seasoned executive who brings a strong pedigree and proven expertise across multiple areas of the life sciences industry,” said Ron Nayot, a Managing Director of Caligor’s parent company, Diversis Capital LLC. “Over a career that spans more than 25 years, David has helped to drive operational excellence at some of the industry’s premier companies. His skill in developing new products, building international brands and guiding organizational growth will provide a solid foundation for our future success.”
“Caligor plays a mission-critical role in reducing risks within the global clinical trial supply chain and assuring the safe, ethical and efficient distribution of comparator drugs on behalf of our clients,” Mr. Edwards said. “Through its investments in people, infrastructure and technology, Diversis is demonstrating its commitment to our business. I’m excited to join such a dynamic, rapidly growing organization. I look forward to applying my experience and leadership to continue to expand our strategic service offerings and our international presence.”
Ms. Bishop joined Caligor as Managing Director in 2010 and served as CEO following the Company’s acquisition by Diversis in 2016, a transaction that she helped lead. Ms. Bishop has more than 25 years of commercial marketing experience in the pharmaceutical industry, having previously served in senior business development and marketing roles at clinical trial supply firms Pharmarama and IDIS Pharmaceuticals.
“Tammy has built great relationships with our clients because she understands the importance of delivering accurate, timely, cost-effective services that enable pharma and biopharma companies to focus on what they do best – improving patient outcomes,” Mr. Nayot said. “As Chief Commercial Officer, she will be Caligor’s primary client interface, ensuring that all functions within the organization are aligned to meet our commercial objectives.
“The appointments of the CEO and CCO for Caligor reflect our investment commitment to this high growth business. The depth of experience across our executive team will enable us to continue to exceed customer expectations globally, and build an industry leading set of integrated strategic clinical trial and global access services,” Mr. Nayot said.
About Caligor
Caligor Opco LLC, a portfolio company of Diversis Capital, LLC, is a global company that manages the regulatory, logistics and supply chain needs for global access programs as well as the sourcing, storing and distribution of comparator drugs for clinical trials. Caligor’s global access programs help to meet the medical needs of patients worldwide by providing access to medicines in situations where the drug has not yet been approved, or is otherwise commercially unavailable. In addition, through its proprietary TrialAssist™ program, Caligor optimizes its services by providing for labeling, QP certification, storage, distribution and destruction of clinical trial and unlicensed medicines managed in the access programs. The Company serves pharmaceutical and biotechnology companies from facilities in Secaucus, New Jersey and Dartford, UK, as well as strategically situated depot locations worldwide. More information is available at http://caligorrx.com/.